Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Q1 2026 earnings

Reported April 30, 2026 · Before market open

Diluted EPS-$0.24Beat by $0.09
Revenue estimate$54.4K
EPS estimate-$0.33

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$108.8K
EPS estimate-$0.26

Financials

Q1 2026

Income statement

See full
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$12.01B+3.3%
Enterprise value$12.03B+3.4%

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0×0.0×
Current ratio7.4×-3.2×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09
Q4 2025-$0.29Miss by $0.19Q3 2025-$0.31Miss by $0.13Q2 2025-$0.76Miss by $0.67Q1 2025-$0.09Beat by $0.00Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Summit Therapeutics report Q1 2026 earnings?
Summit Therapeutics (SMMT) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Summit Therapeutics's Q1 2026 revenue and EPS?
Summit Therapeutics reported diluted EPS of $-0.24 for Q1 2026.
Did Summit Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.33 by $0.09.
How did Summit Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 166.7% from $-0.09.
Where can I find Summit Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001599298-26-000037) and the 10-Q periodic report (0001599298-26-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.